rethinkTHC Search
Menu
Study breakdown

THC absorption from mouth spray varied enormously among older patients, with some absorbing over 15 times more than others

Pilot StudyPreliminary evidence
The takeaway

A pharmacokinetic study of oromucosal THC spray in 20 older medical patients with poor appetite found extremely large inter- and intra-individual variability (40-152% CV), meaning the same dose produced wildly different blood levels across patients.

Geriatricians prescribing cannabis-based medicines, pharmacologists studying cannabinoid dosing, and older patients using THC products.

Variability of 40-152% CV in THC absorption among older patients

What the researchers found

THC pharmacokinetics in older patients showed enormous variability, with coefficient of variation ranging from 40.2% to 152% across pharmacokinetic parameters. A one-compartment model best described THC, with apparent clearance through conversion to THC-OH at 765 L/h. No physiological characteristics including kidney function or body composition significantly influenced pharmacokinetics.

Why it matters

Older adults are an increasingly important population for cannabis-based medicines, yet almost all pharmacokinetic data comes from younger, healthy volunteers. The extreme variability found here means dosing guidelines developed in younger populations may be unreliable for elderly patients.

The numbers in context

20 older patients. Two doses of 2.7 mg THC per spray (2-3 sprays each). THC clearance to THC-OH: 765 L/h. Clearance by other pathways: 162 L/h. Inter- and intra-individual variability: CV 40.2-152%. Absorption modeled with 3 transit compartments.

How the study worked

Twenty older medical patients with poor appetite received two fixed doses of Sativex oromucosal spray (2-3 sprays of 2.7 mg THC each, 4 hours apart). Blood samples were collected for 8 hours. Non-linear mixed-effects modeling developed population pharmacokinetic models for THC and its active metabolite THC-OH.

What this study cannot tell us

Small sample of 20 patients. Single oromucosal product (Sativex). Eight-hour blood sampling may miss later pharmacokinetic phases. Poor appetite itself may affect oromucosal absorption. No comparison with younger adults in the same study.

How to read the evidence

Preliminary: small pilot pharmacokinetic study in 20 patients with a single product and limited sampling duration.

When this study was published

Published 2026.

The bigger picture

As cannabis-based medicines expand into indications like appetite loss, pain, and spasticity in older adults, this study provides the first dedicated pharmacokinetic data in this population and reveals a dosing challenge that will need individualized approaches.

Questions still open

  • What drives the enormous variability in older adults? Would alternative delivery routes (oral capsules, sublingual oils) show less variability? How should clinicians approach dosing when the same dose can produce 15-fold different blood levels?

Common questions

Does age affect how THC is absorbed?
This study found enormous variability in THC absorption among older patients using a mouth spray, with some absorbing vastly more than others from the same dose, and no patient characteristics could predict individual absorption.
Can doctors predict how an older patient will respond to THC?
No. Neither kidney function nor body composition predicted THC levels in this study, suggesting older patients need careful, individualized dose titration.

Read the original research

Population pharmacokinetic modelling revealed large variability in oromucosal absorption of Δ9-tetrahydrocannabinol in older patients with poor appetite.

British journal of clinical pharmacology, 92(2), 504-514

Citation

Storgaard, Ida Klitzing; Nielsen, Rikke Lundsgaard; Houlind, Morten Baltzer; Bornæs, Olivia; Christensen, Louise Westberg Strejby; Andersen, Aino Leegaard; Juul-Larsen, Helle Gybel; Jørgensen, Lillian Mørch; Breindahl, Torben; Jawad, Baker Nawfal; Altintas, Izzet; Andersen, Ove; Lund, Trine Meldgaard. (2026). Population pharmacokinetic modelling revealed large variability in oromucosal absorption of Δ9-tetrahydrocannabinol in older patients with poor appetite.. British journal of clinical pharmacology, 92(2), 504-514. https://doi.org/10.1002/bcp.70284

Explore the wider topic